GILD vs. RVTY: Gilead Sciences vs. Revvity Stock Comparison

November 11, 2026

How do Gilead Sciences (GILD) and Revvity (RVTY) stack up? This page sets them side by side across company profile, performance and risk, profitability, growth, financial strength, dividends, and valuation, with selected fundamentals also measured against each stock's industry-group peers.

Company Profile

Gilead Sciences (GILD) and Revvity (RVTY) both fall under the Pharmaceuticals, Biotechnology & Life Sciences industry group, but GILD is classified in Biotechnology while RVTY is classified in Life Sciences Tools & Services.

Company profile comparison for Gilead Sciences (GILD) and Revvity (RVTY)
Profile Item	GILD	RVTY
Name	Gilead Sciences Inc.	Revvity Inc.
Country/Region	United States	United States
GICS Sector	Health Care	Health Care
GICS Industry Group	Pharmaceuticals, Biotechnology & Life Sciences	Pharmaceuticals, Biotechnology & Life Sciences
GICS Industry	Biotechnology	Life Sciences Tools & Services
GICS Sub-Industry	Biotechnology	Life Sciences Tools & Services
Market Capitalization	207.00 billion USD	17.31 billion USD
Currency	USD	USD
Exchange	Nasdaq	NYSE
Listing Date	January 22, 1992	February 21, 1973
Security Type	Common Stock	Common Stock

Price Performance

Cumulative Growth

GILD

RVTY

GSPC

Gilead Sciences (GILD) vs. Revvity (RVTY), with S&P 500 (GSPC) for reference: Growth of a $10,000 investment over the past five years. Adjusted for dividends and splits.

Trailing Returns

Loading price history…

Trailing total returns for Gilead Sciences (GILD) and Revvity (RVTY). Returns over one year are annualized.

Calendar-Year Returns

Loading price history…

Calendar-year total returns for Gilead Sciences (GILD) and Revvity (RVTY). Each bar is that year's total return, measured year-end to year-end.

Performance Metrics

Price performance metrics for Gilead Sciences (GILD) and Revvity (RVTY)
Metric	GILD	RVTY
Total Return (1Y)	45.69%	76.75%
Total Return (3Y, Annualized)	35.30%	24.22%
Total Return (5Y, Annualized)	25.00%	-1.48%

Risk Profile

Drawdown History

GILD

RVTY

GSPC

Gilead Sciences (GILD) vs. Revvity (RVTY), with S&P 500 (GSPC) for reference: Drawdown from the running peak over the past five years. Each line shows the decline from its prior peak; 0% marks a new high.

Return Distribution

Loading price history…

Distribution of monthly total returns for Gilead Sciences (GILD) and Revvity (RVTY). Each bar is the share of months whose return fell in that 5% bucket.

Risk Metrics

Risk profile metrics for Gilead Sciences (GILD) and Revvity (RVTY)
Metric	GILD	RVTY
Volatility (1Y, Annualized)	27.57%	40.22%
Beta (5Y)	0.36	1.07
Max Drawdown (5Y)	-26.59%	-59.01%
Avg. Volume (3M)	5.98M	1.89M

Risk-Adjusted Performance

Risk-Return Positioning

GILD and RVTY are plotted by 1-year volatility (risk) and 1-year return. The dashed Capital Allocation Line runs from the risk-free rate through the shared industry median.

Risk-Adjusted Metrics

Risk-adjusted metrics for Gilead Sciences (GILD) and Revvity (RVTY)
Metric	GILD	RVTY
Sharpe Ratio (1Y)	1.50	1.80
Sortino Ratio (1Y)	2.48	2.90

Profitability

ROE (TTM)

Gilead Sciences (GILD) reports a negative ROE of -22.45%; negative ROE can reflect losses or negative shareholders’ equity, so it is harder to read as capital efficiency. Meanwhile Revvity (RVTY) reports 3.45%, ranking against industry peers normally.

GILD

Pharmaceuticals, Biotechnology & Life Sciences industry group

-22.45%

Max: 109.18%
Q3: 6.23%
GILD: -22.45%
Median: -26.66%
Q1: -64.05%
Min: -167.77%

RVTY

Pharmaceuticals, Biotechnology & Life Sciences industry group

3.45%

Max: 109.18%
Q3: 6.23%
RVTY: 3.45%
Median: -26.66%
Q1: -64.05%
Min: -167.77%

Gilead Sciences (GILD) vs. Revvity (RVTY): A comparison of their ROE against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Net Margin (TTM)

Gilead Sciences (GILD) reports a negative net margin of -12.46%, usually indicating a net loss over the period. Meanwhile Revvity (RVTY) reports 8.61%, ranking against industry peers normally.

GILD

Pharmaceuticals, Biotechnology & Life Sciences industry group

-12.46%

Max: 18.05%
Q3: 4.78%
Median: 0.00%
Q1: -4.14%
GILD: -12.46%
Min: -17.05%

RVTY

Pharmaceuticals, Biotechnology & Life Sciences industry group

8.61%

Max: 18.05%
RVTY: 8.61%
Q3: 4.78%
Median: 0.00%
Q1: -4.14%
Min: -17.05%

Gilead Sciences (GILD) vs. Revvity (RVTY): A comparison of their net margin against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Operating Margin (TTM)

Both Gilead Sciences (GILD) at 42.43% and Revvity (RVTY) at 17.06% convert sales into operating profit at a top-quartile rate, pointing to tighter cost discipline before financing and tax.

GILD

Pharmaceuticals, Biotechnology & Life Sciences industry group

42.43%

Max: 83.12%
GILD: 42.43%
Q3: 14.77%
Median: 0.00%
Q1: -78.82%
Min: -207.40%

RVTY

Pharmaceuticals, Biotechnology & Life Sciences industry group

17.06%

Max: 83.12%
RVTY: 17.06%
Q3: 14.77%
Median: 0.00%
Q1: -78.82%
Min: -207.40%

Gilead Sciences (GILD) vs. Revvity (RVTY): A comparison of their operating margin against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Profitability Metrics

Profitability metrics for Gilead Sciences (GILD) and Revvity (RVTY)
Metric	GILD	RVTY
ROE (TTM)	-22.45%	3.45%
ROA (TTM)	13.47%	2.54%
Net Margin (TTM)	-12.46%	8.61%
Operating Margin (TTM)	42.43%	17.06%
Gross Margin (TTM)	79.95%	55.91%

Growth

Revenue Growth

Both Gilead Sciences (GILD) at 2.39% and Revvity (RVTY) at 3.67% land near their industries' usual revenue growth ranges, so top-line momentum looks broadly in line with peers on both sides.

Gilead Sciences (GILD) vs. Revvity (RVTY): A comparison of their Revenue Growth across different time periods.

EPS Growth

Gilead Sciences (GILD) at 1,684.21% clears its industry range for EPS growth, a much stronger earnings trajectory than Revvity (RVTY) at -5.91%, which is closer to a typical peer reading.

Gilead Sciences (GILD) vs. Revvity (RVTY): A comparison of their EPS Growth across different time periods.

Growth Metrics

Growth metrics for Gilead Sciences (GILD) and Revvity (RVTY)
Metric	GILD	RVTY
Revenue Growth (YoY)	2.39%	3.67%
Revenue Growth (3Y CAGR)	2.57%	-4.82%
EPS Growth (YoY)	1,684.21%	-5.91%
EPS Growth (3Y CAGR)	23.04%	-23.26%

Financial Strength

Current Ratio (MRQ)

Revvity (RVTY) at 2.65 keeps current ratio within its industry’s typical mid-range, while Gilead Sciences (GILD) at 1.38 runs in the tighter-liquidity quartile — a thinner cushion against current liabilities for GILD.

GILD

Pharmaceuticals, Biotechnology & Life Sciences industry group

1.38

Max: 25.13
Q3: 12.13
Median: 5.52
Q1: 2.47
GILD: 1.38
Min: 0.10

RVTY

Pharmaceuticals, Biotechnology & Life Sciences industry group

2.65

Max: 25.13
Q3: 12.13
Median: 5.52
RVTY: 2.65
Q1: 2.47
Min: 0.10

Gilead Sciences (GILD) vs. Revvity (RVTY): A comparison of their current ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Debt / Equity (MRQ)

Revvity (RVTY) at 0.38 is near its industry mid-range for debt-to-equity ratio, while Gilead Sciences (GILD) at 2.02 sits above its benchmark range, pointing to a heavier debt load relative to equity.

GILD

Pharmaceuticals, Biotechnology & Life Sciences industry group

2.02

GILD: 2.02
Max: 1.42
Q3: 0.65
Median: 0.15
Q1: 0.02
Min: 0.00

RVTY

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.38

Max: 1.42
Q3: 0.65
RVTY: 0.38
Median: 0.15
Q1: 0.02
Min: 0.00

Gilead Sciences (GILD) vs. Revvity (RVTY): A comparison of their debt-to-equity ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Financial Strength Metrics

Financial strength metrics for Gilead Sciences (GILD) and Revvity (RVTY)
Metric	GILD	RVTY
Current Ratio (MRQ)	1.38	2.65
Debt / Equity (MRQ)	2.02	0.38
Net Debt / EBITDA	1.25	2.43

Dividends

Dividend Yield (TTM)

Both Gilead Sciences (GILD) at 1.94% and Revvity (RVTY) at 0.19% yield above their industries’ entire benchmark ranges — high enough that dividend safety, not income, becomes the first question.

GILD

Pharmaceuticals, Biotechnology & Life Sciences industry group

1.94%

GILD: 1.94%
Max: 0.00%
Q3: 0.00%
Median: 0.00%
Q1: 0.00%
Min: 0.00%

RVTY

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.19%

RVTY: 0.19%
Max: 0.00%
Q3: 0.00%
Median: 0.00%
Q1: 0.00%
Min: 0.00%

Gilead Sciences (GILD) vs. Revvity (RVTY): A comparison of their dividend yield against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Dividend Payout Ratio (TTM)

Both Gilead Sciences (GILD) at 43.46% and Revvity (RVTY) at 13.40% pay out more of their earnings than any of their industry peers — the thinnest cover in their groups, so dividend headroom deserves attention.

GILD

Pharmaceuticals, Biotechnology & Life Sciences industry group

43.46%

GILD: 43.46%
Max: 0.00%
Q3: 0.00%
Median: 0.00%
Q1: 0.00%
Min: 0.00%

RVTY

Pharmaceuticals, Biotechnology & Life Sciences industry group

13.40%

RVTY: 13.40%
Max: 0.00%
Q3: 0.00%
Median: 0.00%
Q1: 0.00%
Min: 0.00%

Gilead Sciences (GILD) vs. Revvity (RVTY): A comparison of their payout ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Dividend Metrics

Dividend metrics for Gilead Sciences (GILD) and Revvity (RVTY)
Metric	GILD	RVTY
Dividend Yield (TTM)	1.94%	0.19%
Dividend Payout Ratio (TTM)	43.46%	13.40%

Valuation

P/E Ratio (TTM)

An earnings multiple is available for just one side: Revvity (RVTY) trades at 68.94 times trailing earnings, ranked against its peers, while Gilead Sciences (GILD) has no P/E ratio this period.

GILD

Pharmaceuticals, Biotechnology & Life Sciences industry group

Max: 85.34
Q3: 43.46
Median: 26.69
Q1: 13.30
Min: 0.07
GILD: --

RVTY

Pharmaceuticals, Biotechnology & Life Sciences industry group

68.94

Max: 85.34
RVTY: 68.94
Q3: 43.46
Median: 26.69
Q1: 13.30
Min: 0.07

Gilead Sciences (GILD) vs. Revvity (RVTY): GILD does not report P/E ratio, so it has no value marker; RVTY is benchmarked against the Pharmaceuticals, Biotechnology & Life Sciences industry group.

P/S Ratio (TTM)

On P/S ratio, both Gilead Sciences (GILD) at 6.68 and Revvity (RVTY) at 5.88 are priced roughly in line with their industries — neither looks cheap nor rich on a sales basis.

GILD

Pharmaceuticals, Biotechnology & Life Sciences industry group

6.68

Max: 58.18
Q3: 25.77
Median: 7.30
GILD: 6.68
Q1: 3.01
Min: 0.01

RVTY

Pharmaceuticals, Biotechnology & Life Sciences industry group

5.88

Max: 58.18
Q3: 25.77
Median: 7.30
RVTY: 5.88
Q1: 3.01
Min: 0.01

Gilead Sciences (GILD) vs. Revvity (RVTY): A comparison of their P/S ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

P/B Ratio (MRQ)

Revvity (RVTY) at 2.39 sits near its industry’s typical P/B ratio, while Gilead Sciences (GILD) at 15.88 prices above its benchmark range — GILD looks rich relative to book.

GILD

Pharmaceuticals, Biotechnology & Life Sciences industry group

15.88

GILD: 15.88
Max: 13.53
Q3: 6.54
Median: 3.25
Q1: 1.69
Min: -5.59

RVTY

Pharmaceuticals, Biotechnology & Life Sciences industry group

2.39

Max: 13.53
Q3: 6.54
Median: 3.25
RVTY: 2.39
Q1: 1.69
Min: -5.59

Gilead Sciences (GILD) vs. Revvity (RVTY): A comparison of their P/B ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Valuation Metrics

Valuation metrics for Gilead Sciences (GILD) and Revvity (RVTY)
Metric	GILD	RVTY
P/E Ratio (TTM)	--	68.94
P/S Ratio (TTM)	6.68	5.88
P/B Ratio (MRQ)	15.88	2.39
Free Cash Flow Yield (TTM)	5.16%	3.62%